天演药业与ConjugateBio达成合作，共同开发创新抗体偶联药物（ADC）

天演药业Adagene2025-07-08

公司今日宣布，与ConjugateBio Inc.达成合作，天演将向合作方提供自主研发抗体，共同开发双特异性抗体偶联药物（ADC）。“ConjugateBio 优化抗体偶联药物（ADC）开发流程的能力令人印象深刻，我们很荣幸能提供自主研发的独特抗体来支持合作。通过将该抗体与多种有效载荷结合，ConjugateBio 正推动 ADC 领域的创新发展。借助于我们抗体研发的核心优势，我们很高兴能参与贡献...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2549254188?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-08 19:00","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2549254188","market":"us","top_or_hot":-1,"title":"天演药业与ConjugateBio达成合作，共同开发创新抗体偶联药物（ADC）","media":"天演药业Adagene","content":"<div>\n<p>公司今日宣布，与ConjugateBio Inc.达成合作，天演将向合作方提供自主研发抗体，共同开发双特异性抗体偶联药物（ADC）。“ConjugateBio 优化抗体偶联药物（ADC）开发流程的能力令人印象深刻，我们很荣幸能提供自主研发的独特抗体来支持合作。通过将该抗体与多种有效载荷结合，ConjugateBio 正推动 ADC 领域的创新发展。借助于我们抗体研发的核心优势，我们很高兴能参与贡献...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708191237a43df4cf&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>天演药业与ConjugateBio达成合作，共同开发创新抗体偶联药物（ADC）</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n天演药业与ConjugateBio达成合作，共同开发创新抗体偶联药物（ADC）\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-08 19:00 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708191237a43df4cf&s=b><strong>天演药业Adagene</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>公司今日宣布，与ConjugateBio Inc.达成合作，天演将向合作方提供自主研发抗体，共同开发双特异性抗体偶联药物（ADC）。“ConjugateBio 优化抗体偶联药物（ADC）开发流程的能力令人印象深刻，我们很荣幸能提供自主研发的独特抗体来支持合作。通过将该抗体与多种有效载荷结合，ConjugateBio 正推动 ADC 领域的创新发展。借助于我们抗体研发的核心优势，我们很高兴能参与贡献...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708191237a43df4cf&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4080","symbol_name":"零售业房地产投资信托","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708191237a43df4cf&s=b","article_id":"2549254188","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708191237a43df4cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2549254188","pubTimestamp":1751972419,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"公司今日宣布，与ConjugateBio Inc.达成合作，天演将向合作方提供自主研发抗体，共同开发双特异性抗体偶联药物。Kum Yoo 博士ConjugateBio联合创始人兼首席执行官根据协议条款，天演药业将获得一笔未公开的预付款，以及里程碑和特许权使用费支付。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4080":"零售业房地产投资信托","ADAG":"天演药业","BK4139":"生物科技","ADC":"艾格里房产","BK4231":"零售房地产信托"},"translate_title":"Tianyan Pharmaceutical and ConjugateBio have reached a cooperation to jointly develop innovative antibody conjugate drugs (ADCs)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ADAG":1,"ADC":1},"content_text":"公司今日宣布，与ConjugateBio Inc.达成合作，天演将向合作方提供自主研发抗体，共同开发双特异性抗体偶联药物（ADC）。“ConjugateBio 优化抗体偶联药物（ADC）开发流程的能力令人印象深刻，我们很荣幸能提供自主研发的独特抗体来支持合作。通过将该抗体与多种有效载荷结合，ConjugateBio 正推动 ADC 领域的创新发展。借助于我们抗体研发的核心优势，我们很高兴能参与贡献到ADC这个不断增长的市场中！据估计到 2030 年，全球 ADC 市场规模将突破 300 亿美元。”罗培志 博士天演药业首席执行官兼研发总裁“天演药业在抗体发现领域展现出的卓越能力和独特优势，让我们坚信，双方合作有望开发出全新、高效且安全的抗体偶联药物（ADC）。正如ADG126所展现的积极数据，天演在开发兼具高耐受性和显著疗效的候选分子方面不断突破，为本次合作奠定了坚实基础。”Kum Yoo 博士ConjugateBio联合创始人兼首席执行官根据协议条款，天演药业将获得一笔未公开的预付款，以及里程碑和特许权使用费支付。天演药业保留该合作抗体在抗体偶联药物（ADC）以外的所有权利。关于天演药业天演药业（纳斯达克股票代码：ADAG）是平台驱动并拥有自主平台产出的临床产品开发阶段的生物制药公司，公司致力于发现并开发以原创抗体为基石的新型癌症免疫疗法。借力于计算生物学与人工智能，凭借其全球首创的三体平台技术(新表位抗体NEObody™，安全抗体SAFEbody®及强力抗体POWERbody™)，天演药业已建立起聚焦于新型肿瘤免疫疗法的独特原创的抗体产品线，以解决尚未满足的临床需求。天演已和多个全球知名合作伙伴达成了战略合作关系，并以其多种原创前沿科技为合作伙伴的新药研发赋能。更多信息请访问：https://investor.adagene.com并关注天演药业微信、领英及推特官方帐号SAFEbody®为天演在美国、中国、澳大利亚、日本、新加坡和欧盟的注册商标。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2549254188","isCrawlerRequest":true}